Mustang Bio, Inc. (NASDAQ:MBIO) Short Interest Up 37.3% in March

Mustang Bio, Inc. (NASDAQ:MBIO) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 60,400 shares, a growth of 37.3% from the March 15th total of 44,000 shares. Based on an average trading volume of 221,200 shares, the days-to-cover ratio is presently 0.3 days. Currently, 3.1% of the company’s shares are short sold.

Hedge Funds Weigh In On Mustang Bio

An institutional investor recently raised its position in Mustang Bio stock. Geode Capital Management LLC increased its holdings in Mustang Bio, Inc. (NASDAQ:MBIO) by 15.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 284,437 shares of the company’s stock after purchasing an additional 38,951 shares during the quarter. Geode Capital Management LLC owned approximately 29.63% of Mustang Bio worth $50,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 9.95% of the stock is currently owned by hedge funds and other institutional investors.

Mustang Bio Stock Down 0.7 %

Shares of NASDAQ MBIO opened at $1.33 on Friday. The firm’s fifty day moving average is $1.76 and its 200 day moving average is $6.81. Mustang Bio has a 52 week low of $1.15 and a 52 week high of $65.00. The company has a market cap of $4.40 million, a price-to-earnings ratio of -0.02 and a beta of 2.14.

About Mustang Bio

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.